Every one of those 1 sits in a single category, clinical-trial. AtaiBeckley is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Treatment-Resistant Depression appears in 1 tracked Biotech story from March 8, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Treatment-Resistant Depression
Every one of those 1 sits in a single category, clinical-trial. AtaiBeckley is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Treatment-Resistant Depression appears in 1 tracked Biotech story from March 8, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Treatment-Resistant Depression. Shared-story counts are live from our verified record — not editorial picks.
AtaiBeckley (ATAI) has confirmed the Q2 2026 launch of its Phase 3 program for BPL-003, an intranasal 5-MeO-DMT formulation for Treatment-Resistant Depression. The announcement follows the release of 2025 financial results that show a robust cash position capable of funding pivotal late-stage clinical development.
Treatment-Resistant Depression is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.